Messenger RNA (mRNA) nanoparticle tumour vaccination.

Use of mRNA-based vaccines for tumour immunotherapy has gained increasing attention in recent years. A growing number of studies applying nanomedicine concepts to mRNA tumour vaccination show that the mRNA delivered in nanoparticle format can generate a more robust immune response. Advances in the past decade have deepened our understanding of gene delivery barriers, mRNA's biological stability and immunological properties, and support the notion for engineering innovations tailored towards a more efficient mRNA nanoparticle vaccine delivery system. In this review we will first examine the suitability of mRNA for engineering manipulations, followed by discussion of a model framework that highlights the barriers to a robust anti-tumour immunity mediated by mRNA encapsulated in nanoparticles. Finally, by consolidating existing literature on mRNA nanoparticle tumour vaccination within the context of this framework, we aim to identify bottlenecks that can be addressed by future nanoengineering research.

Full Text

Duke Authors

Cited Authors

  • Phua, KK; Nair, SK; Leong, KW

Published Date

  • July 2014

Published In

Volume / Issue

  • 6 / 14

Start / End Page

  • 7715 - 7729

PubMed ID

  • 24904987

Electronic International Standard Serial Number (EISSN)

  • 2040-3372

International Standard Serial Number (ISSN)

  • 2040-3364

Digital Object Identifier (DOI)

  • 10.1039/c4nr01346h

Language

  • eng